ENZ Spike Higher After FDA EUA For Its AMPIPROBE
Shares Of Enzo Life Sciences Spike Higher After Co. Gets FDA Emergency Use Authorization For Its AMPIPROBE Coronavirus Test System
Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.
The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product."
fda.gov/media/139829/download
seekingalpha.com/news/3589753-fda-oks-emergency-use-of-enzo-bios-covidminus-19-test
Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.
The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product."
fda.gov/media/139829/download
seekingalpha.com/news/3589753-fda-oks-emergency-use-of-enzo-bios-covidminus-19-test
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.